First-Line Oral Treatment for Hip Osteoarthritis
Selecting appropriate first-line oral pharmacological therapy for hip osteoarthritis requires careful consideration of patient-specific risk factors that influence both agent selection and co-therapy requirements.
This structured protocol covers first-line oral management of hip osteoarthritis, with the regimen tailored to individual patient risk profiles — particularly gastrointestinal risk — and to cases where the primary oral approach is contraindicated or not tolerated.
Treatment approach — partial summary
First-line management involves oral analgesic or anti-inflammatory therapy. Patients with elevated gastrointestinal risk require specific gastroprotective co-therapy, and a separate oral alternative is recommended when the primary agent is contraindicated or not tolerated. The complete structured regimen — including agent selection criteria and the full clinical algorithm — is available below.
References
- Oral NSAIDs were generally recommended for all sites of OA, but strength of recommendations (conditional/weak versus strong) varied among guidelines, primarily reflecting concerns about adverse effects.
- Acetaminophen is no longer considered "first-line" for OA due to its relative poor efficacy, though it is still an option for those who have contraindications or intolerances to NSAIDs.
- Consider adding proton pump inhibitor or misoprostol in patients at risk for upper gastrointestinal events who require treatment with NSAIDs or COX-2 inhibitors.
DOI: 10.1016/j.rdc.2022.03.009.
View source ↗